Mostrando 10 resultados de: 14
Filtros aplicados
Publisher
Current Drug Targets(2)
European Journal of Clinical Pharmacology(2)
Pharmacopsychiatry(2)
European Journal of Drug Metabolism and Pharmacokinetics(1)
Expert Opinion on Drug Metabolism and Toxicology(1)
Área temáticas
Farmacología y terapéutica(11)
Ginecología, obstetricia, pediatría, geriatría(2)
Medicina y salud(2)
Bioquímica(1)
Fisiología humana(1)
Origen
scopus(14)
Clinical implications of CYP2D6 genetic polymorphism during treatment with antipsychotic drugs
ReviewAbstract: CYP2D6 is described as the most relevant enzyme in the metabolism of many antipsychotic drugs. Its cPalabras claves:Antipsychotic drugs, CYP2D6, pharmacogenetics, PharmacogenomicsAutores:Adrián LLerena, Berecz R., Cáceres M.C., Dorado P., Penãs-Lledó E.M.Fuentes:scopusClozapine withdrawal symptoms after change to sertindole in a schizophrenic patient
ArticleAbstract: A 30-year-old male patient with paranoid schizophrenia was on clozapine therapy for more than five yPalabras claves:Autores:Adrián LLerena, Berecz R., De la Rubia A., Degrell I., Glaub T., Kellermann M.Fuentes:scopusAntibiotic use in 3 European university hospitals
ArticleAbstract: The use of antibiotic drugs was studied in university teaching hospitals in Tartu, Estonia, HuddingePalabras claves:Autores:Adrián LLerena, Berecz R., Dahl M.L., Kiivet R.A., Maimets M., Wettermark B.Fuentes:scopusAntipsychotic drugs and QTc prolongation: The potential role of CYP2D6 genetic polymorphism
ReviewAbstract: Although the most common, and usually serious, side effects of first-generation (or typical) antipsyPalabras claves:Antipsychotic drugs, Cardiac side effects, CYP2D6, drug metabolism, QT interval lengthening, Torsades de pointes-type arrhythmiaAutores:Adrián LLerena, Berecz R., Dorado P., Penãs-Lledó E.M.Fuentes:scopusDetermination of fluoxetine and norfluoxetine in human plasma by high-performance liquid chromatography with ultraviolet detection in psychiatric patients
ArticleAbstract: A rapid high-performance liquid chromatographic method is described for the simultaneous determinatiPalabras claves:Fluoxetine, NorfluoxetineAutores:Adrián LLerena, Berecz R., Cáceres M.C., De la Rubia A., Dorado P., González A.P., Jesus Norberto M.Fuentes:scopusCYP2C9 gene and susceptibility to major depressive disorder
ArticleAbstract: Alteration of monoaminergic neurotransmission has been implicated in the pathophysiology of mood disPalabras claves:CYP2C9 gene, Depression, SchizophreniaAutores:Adrián LLerena, Berecz R., De la Rubia A., Dorado P., González A.P., Penãs-Lledó E.M.Fuentes:scopusEffect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes
ArticleAbstract: Sixteen hospitalized white European Spanish psychiatric patients treated with thioridazine alone werPalabras claves:CYP2D6, debrisoquine, Inhibition, ThioridazineAutores:Adrián LLerena, Berecz R., De la Rubia A., Dorado P., Fernández-Salguero P.Fuentes:scopusNo effect of the CYP1A2*1F genotype on thioridazine, mesoridazine, sulforidazine plasma concentrations in psychiatric patients [2]
OtherAbstract:Palabras claves:Autores:Adrián LLerena, Berecz R., De la Rubia A., Dorado P., Penãs-Lledó E.M.Fuentes:scopusPharmacogenetics of clinical response to risperidone
ReviewAbstract: Despite risperidones proven safety and efficacy, existing pharmacogenetic knowledge could be appliedPalabras claves:Biomarkers, Clinical outcome, pharmacogenetics, Risperidone, side effectsAutores:Adrián LLerena, Berecz R., Humberto Fariñas, Penãs-Lledó E.M., Süveges A.Fuentes:scopusQTc interval lengthening and debrisoquine metabolic ratio in psychiatric patients treated with oral haloperidol monotherapy
OtherAbstract:Palabras claves:debrisoquine, Haloperidol, QTcAutores:Adrián LLerena, Berecz R., De la Rubia A., Dorado P.Fuentes:scopus